Innoviva Basic Shares Outstanding 2010-2024 | INVA
Innoviva basic shares outstanding from 2010 to 2024. Basic shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares.
Innoviva Annual Basic Shares Outstanding
(Millions of US $) |
| 2023 |
$65 |
| 2022 |
$70 |
| 2021 |
$82 |
| 2020 |
$101 |
| 2019 |
$101 |
| 2018 |
$101 |
| 2017 |
$107 |
| 2016 |
$110 |
| 2015 |
$115 |
| 2014 |
$112 |
| 2013 |
$102 |
| 2012 |
$91 |
| 2011 |
$82 |
| 2010 |
$72 |
| 2009 |
$63 |
Innoviva Quarterly Basic Shares Outstanding
(Millions of US $) |
| 2024-09-30 |
$63 |
| 2024-06-30 |
$63 |
| 2024-03-31 |
$63 |
| 2023-12-31 |
$65 |
| 2023-09-30 |
$65 |
| 2023-06-30 |
$65 |
| 2023-03-31 |
$68 |
| 2022-12-31 |
$70 |
| 2022-09-30 |
$70 |
| 2022-06-30 |
$70 |
| 2022-03-31 |
$70 |
| 2021-12-31 |
$82 |
| 2021-09-30 |
$69 |
| 2021-06-30 |
$88 |
| 2021-03-31 |
$101 |
| 2020-12-31 |
$101 |
| 2020-09-30 |
$101 |
| 2020-06-30 |
$101 |
| 2020-03-31 |
$101 |
| 2019-12-31 |
$101 |
| 2019-09-30 |
$101 |
| 2019-06-30 |
$101 |
| 2019-03-31 |
$101 |
| 2018-12-31 |
$101 |
| 2018-09-30 |
$101 |
| 2018-06-30 |
$101 |
| 2018-03-31 |
$101 |
| 2017-12-31 |
$107 |
| 2017-09-30 |
$107 |
| 2017-06-30 |
$108 |
| 2017-03-31 |
$107 |
| 2016-12-31 |
$110 |
| 2016-09-30 |
$109 |
| 2016-06-30 |
$111 |
| 2016-03-31 |
$112 |
| 2015-12-31 |
$115 |
| 2015-09-30 |
$116 |
| 2015-06-30 |
$115 |
| 2015-03-31 |
$115 |
| 2014-12-31 |
$112 |
| 2014-09-30 |
$113 |
| 2014-06-30 |
$111 |
| 2014-03-31 |
$110 |
| 2013-12-31 |
$102 |
| 2013-09-30 |
$106 |
| 2013-06-30 |
$98 |
| 2013-03-31 |
$96 |
| 2012-12-31 |
$96 |
| 2012-09-30 |
$95 |
| 2012-06-30 |
$89 |
| 2012-03-31 |
$84 |
| 2011-12-31 |
$82 |
| 2011-09-30 |
$82 |
| 2011-06-30 |
$82 |
| 2011-03-31 |
$81 |
| 2010-12-31 |
$72 |
| 2010-09-30 |
$74 |
| 2010-06-30 |
$73 |
| 2010-03-31 |
$65 |
| 2009-12-31 |
$63 |
| 2009-09-30 |
$63 |
| 2009-06-30 |
$63 |
| 2009-03-31 |
$62 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.201B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
